Comparison of clinical effects of bucillamine between additive combination and single administration study in rheumatoid arthritis.
In a multicentre double blind study, it was demonstrated that bucillamine (Bu) 100 mg was more effective than placebo in patients with rheumatoid arthritis who are partially remitted by gold injections for more than six months. Global effectiveness and usefulness rates of 100 mg Bu in the combination therapy were almost the same as those of 3200 mg Bu in single administration. Side effects were also similar in the two regimens.